Bacteria battling syringes in a futuristic hospital environment, symbolizing antibiotic resistance.

ESBL and CRE: How to Protect Yourself from Antibiotic-Resistant Superbugs

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 3 min read.

"A Korean study reveals the prevalence and transmission rates of ESBL-E and CRE in intensive care units, highlighting the importance of hygiene and surveillance in combating antibiotic resistance."


Infections caused by antibiotic-resistant bacteria are on the rise, posing a significant threat to public health. Among these, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) and carbapenem-resistant Enterobacteriaceae (CRE) are particularly concerning. These bacteria are resistant to many common antibiotics, making infections difficult to treat.

A recent study conducted in Korea investigated the prevalence and transmission rates of ESBL-E and CRE in intensive care units (ICUs). The findings shed light on the challenges healthcare facilities face in controlling the spread of these superbugs. The study underscores the importance of proactive measures to protect vulnerable patients.

This article breaks down the study's key findings, explaining what ESBL-E and CRE are, how they spread, and, most importantly, what you can do to minimize your risk of infection. Understanding these threats is the first step in safeguarding your health and that of your loved ones.

AI Search Multiple angles on this topic

Growing Global Burden

Antimicrobial resistance in Escherichia coli, particularly ESBL-producing and carbapenem-resistant strains, is described as a serious global health threat. These strains are associated with increased morbidity, mortality, and healthcare costs because they limit the effectiveness of standard antibiotic therapies. A 2025 study examined multidrug-resistant and ESBL-producing E. coli using the ATLAS global dataset from 64 countries across six continents between 2004 and 2022. The WHO identifies effective infection prevention and control as a cornerstone of action against antimicrobial resistance and a key strategy for addressing international public-health threats.

Detection and Treatment Constraints

Current antimicrobial-resistance detection methods include culture-based approaches, but they have important limitations in sensitivity and turnaround time. They may also fail to detect all potential resistance genes, creating an unmet clinical need for improved testing. ESBL-producing bacteria develop resistance through production of extended-spectrum beta-lactamase enzymes. The 2026 IDSA AMR Guidance provides treatment suggestions for ESBL-producing Enterobacterales, AmpC-producing Enterobacterales, CRE, difficult-to-treat Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii.

Understanding ESBL-E and CRE: What are These Superbugs?

Bacteria battling syringes in a futuristic hospital environment, symbolizing antibiotic resistance.

ESBL-E and CRE are types of bacteria that have developed resistance to multiple antibiotics. This resistance is due to enzymes they produce: ESBLs (extended-spectrum beta-lactamases) in the case of ESBL-E, and mechanisms that resist carbapenems in CRE.

Here's a simple breakdown:

  • ESBL-E: These bacteria produce enzymes (ESBLs) that break down many common antibiotics, including penicillins and cephalosporins. Common examples include Escherichia coli (E. coli) and Klebsiella pneumoniae.
  • CRE: These bacteria are resistant to carbapenems, which are often used as a last-resort antibiotic for serious infections. CRE infections can be particularly difficult to treat because they are often resistant to almost all available antibiotics.
AI Search Multiple angles on this topic

New York City NDM Increase

CDC surveillance reported an increase in New York City NDM-positive carbapenem-resistant Enterobacterales cases from 58 in 2019 to 388 in 2024. In 2024, NDM-positive CRE cases surpassed KPC-positive CRE cases. The report highlights a changing distribution of carbapenem-resistance mechanisms in the city over that period.

Variation Limits Generalization

A 2026 systematic review and meta-analysis found that ESBL production was common in isolate-level evidence, but extreme heterogeneity limited generalisability. This means prevalence findings may vary substantially by region and between studies. CDC surveillance data can also be updated, so analyses performed on datasets generated on different dates may produce slightly different results. Together, these limitations caution against treating one estimate as universally representative.

ESBL and CRE Incidence

CDC data for 2023 reported crude incidence rates of 2.0 cases per 100,000 persons for carbapenem-resistant Acinetobacter baumannii, 7.7 for CRE, and 201.2 for ESBL-producing Enterobacterales at participating EIP sites. In a separate CDC study of children in the United States, the overall annual CRE incidence rate across EIP sites from 2016 through 2020 was 0.70 cases per 100,000 pediatric population. The same pediatric study reported an annual ESBL-E incidence rate of 23.08 during its 1.5-year period, declining from 26.54 in 2019 to 19.63 in 2020. These figures come from different surveillance populations and periods and should not be treated as directly interchangeable.

The rise of ESBL-E and CRE is linked to the overuse and misuse of antibiotics, which creates an environment where resistant bacteria can thrive. These bacteria are often found in hospitals and other healthcare settings, where antibiotic use is high and patients are more vulnerable to infection.

Taking Control: Your Role in Combating Antibiotic Resistance

While the threat of antibiotic-resistant bacteria is serious, understanding the risks and taking proactive steps can help protect you and your community. By practicing good hygiene, using antibiotics responsibly, and advocating for better infection control measures, we can all play a role in slowing the spread of these dangerous superbugs.

AI Search Multiple angles on this topic

Why ESBL Infections Matter

Reviews describe infections with multidrug-resistant strains as causing greater mortality, morbidity, and economic losses than infections involving susceptible strains. Urinary tract infection is identified as a typical infection associated with ESBL-producing Enterobacteriaceae. A separate meta-analysis focuses on the global prevalence and antibiotic-resistance patterns of ESBL-producing E. coli in clinical isolates, emphasizing resistance to multiple antibiotics, especially beta-lactams.

Emerging Tools and Strategies

A 2025 publication examines antimicrobial resistance in ESBL- and carbapenem-resistant Escherichia coli as an emerging threat. Proposed future strategies in another review include novel antibiotics, CRISPR technology, vaccine innovations, and public-private partnerships. The review presents these approaches as potential solutions to the escalating resistance crisis. Their inclusion reflects a forward-looking research agenda rather than established clinical outcomes.

System-Wide Consequences

Antibiotic resistance can adversely affect both clinical and therapeutic outcomes. Reported consequences include treatment failures, the need for expensive alternative drugs, higher morbidity and mortality, longer hospitalizations, and increased healthcare costs. These effects show that resistance is not limited to the question of whether one antibiotic works. It can also place broader financial and operational pressure on healthcare systems.

Treatment in Clinical Practice

A review of antimicrobial resistance examines the molecular and ecological mechanisms underlying resistance and evaluates global containment efforts. A separate real-world study reported experience using meropenem/vaborbactam for infections caused by difficult-to-treat ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. The study assessed this treatment after two years of marketing authorization in a clinical setting with high prevalence of resistance. Its focus illustrates how treatment decisions are evaluated under real-world conditions rather than only in theoretical models.

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly are ESBL-E and CRE?

ESBL-E stands for Extended-Spectrum Beta-Lactamase-producing Enterobacteriaceae. These are bacteria, like E. coli and Klebsiella pneumoniae, that produce ESBL enzymes, rendering many common antibiotics like penicillins and cephalosporins ineffective. CRE stands for Carbapenem-resistant Enterobacteriaceae. These bacteria are resistant to carbapenems, which are powerful antibiotics used as a last resort. Both ESBL-E and CRE infections are difficult to treat due to their resistance to multiple drugs, posing a significant threat, especially in healthcare settings. The rise of these superbugs is a consequence of antibiotic overuse, which fosters an environment where drug-resistant bacteria can thrive.

2

Why are ESBL-E and CRE such a cause for concern?

ESBL-E and CRE are significant because they limit treatment options for bacterial infections. Infections caused by ESBL-E and CRE can lead to longer hospital stays, increased healthcare costs, and higher mortality rates. The spread of these resistant bacteria complicates infection control efforts and poses a serious threat to public health. Effective treatment of infections is further complicated by the limited development of new antibiotics. Containment strategies are crucial to prevent outbreaks particularly in vulnerable populations within intensive care units.

3

What can I do to minimize my risk of getting an infection from ESBL-E or CRE?

To protect yourself from ESBL-E and CRE, practice thorough hand hygiene, especially in healthcare settings. If prescribed antibiotics, take them exactly as directed and complete the full course, avoid misuse. Advocate for stringent infection control practices in hospitals and clinics, such as regular cleaning and screening of patients. Awareness is the first line of defense, promoting responsible antibiotic use and reducing the selective pressure that drives antibiotic resistance.

4

How do ESBL-E and CRE spread from person to person?

The spread of ESBL-E and CRE is often facilitated by poor hygiene practices, overuse of antibiotics, and close contact with infected individuals, particularly in healthcare environments. Bacteria can spread through contaminated surfaces, medical equipment, and direct contact with healthcare workers or patients. Infection control measures, such as hand hygiene and environmental disinfection, are vital in preventing transmission. Surveillance within healthcare facilities is crucial for early detection and containment of outbreaks.

5

How does antibiotic resistance develop in bacteria like ESBL-E and CRE?

Antibiotic resistance happens when bacteria evolve and develop mechanisms to survive exposure to antibiotics. ESBL-E become resistant by producing ESBL enzymes that break down antibiotics. CRE develop resistance through various mechanisms that prevent antibiotics like carbapenems from working. The overuse and misuse of antibiotics accelerate this process by creating selective pressure, where only the resistant bacteria survive and multiply. This leads to a higher prevalence of resistant strains, making infections harder to treat.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.